In vitro antimycobacterial activity of 5-chloropyrazinamide

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 462-463

  Cynamon, Michael H ^a   Speirs, Robert J ^a   Welch, John T ^b  

^a SYRACUSE VA MEDICAL CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLOROPYRAZINAMIDE; 5 CHLOROPYRAZINOIC ACID; PYRAZINAMIDE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; DILUTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE;

EID: 0031941640     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bass, J. B., Jr., L. S. Farer, P. C. Hopewell, R. O'Brien, R. F. Jacobs, F. Ruben, D. E. Snider, Jr., and G. Thornton. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 149:1359-1374.
2. Cynamon, M. H., R. Gimi, F. Gyenes, C. A. Sharpe, K. E. Bergmann, H. J. Han, L. B. Gregor, R. Rapuolu, G. Luciano, and J. T. Welch. 1995. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J. Med. Chem. 38:3902-3907.
3. Cynamon, M. H., S. P. Klemens, T. S. Chou, R. H. Gimi, and J. T. Welch. 1992. antimycobacterial activity of a series of pyrazinoic acid esters. J. Med. Chem. 35:1212-1215.
4. Davidson, P. T., and H. Q. Le. 1992. Drug treatment of tuberculosis. Drugs 43:651-673.
5. Gangadharam, P. R. J., and M. D. Iseman. 1986. Antimycobacterial drugs, p. 17-40. In P. K. Peterson and J. Verhoef. (ed.), The antimicrobial agents annual. Elsevier, New York, N.Y.
6. Grosset, J. H. 1990. Present and new drug regimens in chemotherapy and chemoprophylaxis of tuberculosis. Bull. Int. Union Tuberc. Lung Dis. 65:86-91.
7. Heifets, L. B., M. A. Flory, and P. J. Lindholm-Levy. 1989. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? Antimicrob. Agents Chemother. 33:1252-1254.
8. Konno, K., F. M. Feldmann, and W. McDermott. 1967. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95:461-469.
9. Lecoeur, H. F., C. Truffot Pernot, and J. H. Grosset. 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140:1189-1193.
10. Scorpio, A., and Y. Zhang. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667.
11. Scorpio, A., P. Lindholm-Levy, L. Heifets, R. Gilman, S. Siddiqi, M. Cynamon, and Y. Zhang. 1997. Characterization of the pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:540-543.
12. Speirs, R. J., J. T. Welch, and M. H. Cynamon. 1995. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Antimicrob. Agents Chemother. 39:1269-1271.
13. Vestal, A. L. 1969. Procedures for the isolation and identification of mycobacteria, p. 113-115. Public Health Service publication no. 1995. Laboratory Division, National Communicable Disease Center, Atlanta, Ga.